NCT01573858已完成不适用
Effect of Acupuncture and Clomiphene Citrate on Live Birth in Anovulatory Women With Polycystic Ovary Syndrome: A Randomized Controlled Trial (PCOSAct)
Heilongjiang University of Chinese Medicine25 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 2012年7月6日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 1,000
- 试验地点
- 25
- 主要终点
- Live birth rate
研究概览
简要总结
The objectives of the present trial are to test the following three hypotheses in anovulatory women with PCOS:
- Acupuncture protocol 1 plus CC (Arm A) is more likely to result in live birth than acupuncture protocol 2 combined with CC (Arm B),
- Acupuncture protocol 2 plus CC (Arm B) is more likely to result in live birth than acupuncture protocol 1 plus placebo (Arm C),
- Acupuncture protocol 1 plus placebo (Arm C) is more likely to result in live birth than acupuncture protocol 2 plus placebo (Arm D).
详细描述
This is a multicenter, randomized, controlled, 2 by 2 factorial clinical trial for Chinese women with PCOS.
Primary outcomes:
- Live birth rate
Secondary outcomes:
- Ovulation rate
- Ongoing pregnancy rate
- Multiple pregnancy rate
- Miscarriage rate
- Hormonal profile
- Metabolic profile
- Side effect profile
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 40 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Inclusion Criteria:
- •Age of women between 20 and 40 years.
- •Confirmed diagnosis of PCOS according to the modified Rotterdam criteria and all subjects must have anovulation plus either polycystic ovaries and/or hyperandro-genism.
- •Patency of at least one tube and a normal uterine cavity shown by hysterosalpingogram, HyCosi or diagnostic laparoscopy.
- •Semen analysis:
- •a. Sperm concentration ≥15×106/ml and b. total motility (a+b+c) ≥40% or forward motility (a+b) ≥32% in the semen analysis of the husband (based on World Health Organization, 2010).
- •Total motile sperm count ≥9 million [based on WHO (2010) criteria, volume 1.5 ml; conc 15 million; motility 40%. 1.5 x 15 x 0.04=9 million].
排除标准
- •Exclusion of other endocrine disorders
- •Patients with hyperprolactinemia (defined as two prolactin levels at least one week apart 25 ng/mL or greater or as determined by local normative values). The goal of eliminating patients with documented hyperprolactinemia is to decrease the heterogeneity of the PCOS population. These patients may be candidates for ovulation induction with alternate regimens (dopamine agonists). A normal level within the last year or on treatment is adequate for entry.
- •Patients with FSH levels > 15 mIU/mL. A normal level within the last year is adequate for entry.
- •Patients with uncorrected thyroid disease (defined as TSH < 0.2 mIU/mL or > 5.5 mIU/mL). A normal level within the last year is adequate for entry.
- •Patients diagnosed with Type I or Type II diabetes who are poorly controlled (defined as a glycohemoglobin level > 7.0%), or patients receiving antidiabetic medications such as insulin, thiazolidinediones, acarbose, or sulfonylureas likely to confound the effects of study medication; patients currently receiving metformin XR for a diagnosis of Type I or Type II diabetes or for PCOS are also specifically excluded.
- •Patients with suspected Cushing's syndrome.
- •Use of hormonal or other medication including Chinese Herbal prescriptions which may affect the outcome at least in the past 2 months.
- •Pregnancy within the past 6 weeks.
- •Within 6 weeks post-abortion or postpartum.
- •Breastfeeding within the last 6 months.
- •Acupuncture within the last 6 months.
- •Not willing to give written consent to the study.
- •Additional exclusion criteria
- •Patients on oral contraceptives, depot progestins, or hormonal implants (including Implanon). A two month washout period will be required prior to screening for patients on these agents. Longer washouts may be necessary for certain depot contraceptive forms or implants, especially where the implants are still in place. A one-month washout will be required for patients on oral cyclic progestins.
- •Patients with liver disease defined as AST or ALT > 2 times normal or total bilirubin >2.5 mg/dL. Patients with renal disease defined as BUN > 30 mg/dL or serum creatinine> 1.4 mg/dL.
- •Patients with significant anemia (Hemoglobin < 10 g/dL).
- •Patients with a history of deep venous thrombosis, pulmonary embolus, or cerebrovascular accident.
- •Patients with known heart disease that is likely to be exacerbated by pregnancy.
- •Patients with a history of, or suspected cervical carcinoma, endometrial carcinoma, or breast carcinoma. A normal Pap smear result will be required for women 21 and over.
- •Patients with a current history of alcohol abuse. Alcohol abuse is defined as > 14 drinks/week or binge drinking.
- •Patients enrolled simultaneously into other investigative studies that require medications, proscribe the study medications, limit intercourse, or otherwise prevent compliance with the protocol.
- •Patients who anticipate taking longer than a one month break during the protocol should not be enrolled.
- •Patients taking other medications known to affect reproductive function or metabolism. These medications include oral contraceptives, GnRH agonists and antagonists, antiandrogens, gonadotropins, anti-obesity drugs, Chinese herbal formula, anti-diabetic drugs such as metformin and thiazolidinediones, somatostatin, diazoxide, ACE inhibitors, and calcium channel blockers. The washout period on all these medications will be two months.
- •Patients with a suspected adrenal or ovarian tumor secreting androgens.
- •Couples with previous sterilization procedures (vasectomy, tubal ligation) which have been reversed. The prior procedure may affect study outcomes, and patients with both a reversed sterilization procedure and PCOS are rare enough that exclusion should not adversely affect recruitment.
- •Subjects who have undergone a bariatric surgery procedure in the recent past (< 12 months) and are in a period of acute weight loss or have been advised against pregnancy by their bariatric surgeon.
- •Patients with untreated poorly controlled hypertension defined as a systolic blood pressure 160 mm Hg or a diastolic 100 mm Hg obtained on two measures obtained at least 60 minutes apart.
- •Patients with known congenital adrenal hyperplasia.
结局指标
主要结局
Live birth rate
时间窗: Up to 3 years
次要结局
- Metabolic profile(Up to 2 years)
- Miscarriage rate(Up to 2 years)
- Side effect profile(Up to 2 years)
- Ongoing pregnancy rate(Aprial 2012 to July 2014 (up to 3 years))
- Multiple pregnancy rate(Up to 2 years)
- Ovulation rate(Up to 3 years)
- Hormonal profile(Up to 2 years)
研究者
Xiaoke Wu
Professor and Department Chairman of Obstetrics and Gynecology
Heilongjiang University of Chinese Medicine
研究点 (25)
Loading locations...
相似试验
已完成
4 期
Effectiveness and Safety of Acupuncture for Climacteric Syndrome in Patients With Breast CancerClimacteric SyndromeNCT01275807Azienda Usl di Bologna190
已完成
不适用
Comparison acupuncture with Clomiphene for ovulation induction in polycystic ovary syndromePolycystic Ovary Syndrome.Polycystic ovarian syndromeF28.2IRCT201512057265N3Mashhad University of Medical Sciences110
已完成
不适用
Differential Effects of Clomiphene Citrate in Women Undergoing SuperovulationMoodNCT01291056University of Utah20
已完成
2 期
Effect of Acupuncture and Low Caloric Diet on Primary Hypothyroidism and Irregular Menstruation in Infertile WomenPrimary HypothyroidismAcupunctureIrregular MenstruationPCONCT05804149Cairo University60
已完成
3 期
The Effects of Letrozole And Clomiphene Citrate For Induction of Ovulation In Polycystic Ovarian Syndrome(PCOS)Polycystic Ovarian SyndromeNCT01577017Nik Hazlina150